Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018

References

• Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–562P. doi:10.2471/BLT.18.22848631384073
   PubMed Web of Science ®Google Scholar
• National Health Commission of the PRC [homepage on Internet]. Overview of the national epidemic of infectious diseases in 2019; 2020 Available from: http://www.nhc.gov.cn/jkj/s3578/202004/b1519e1bc1a944fc8ec176db600f68d1.shtml. Accessed 613, 2020.
   Google Scholar
• National Center for STD Control, Chinese Center for Disease Control and Prevention; Venereology Group, Chinese Society of Dermatology; Subcommittee on Venereology, China Dermatologist Association. Guidelines for diagnosis and treatment of syphilis, gonorrhea and genital Chlamydia trachomatis infection (2020). Chin J Dermatol. 2020;53(3):168–179.
   Google Scholar
• Workowski KA, Bolan GA; Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR–03):1–137.
   PubMed Web of Science ®Google Scholar
• Australian Sexual Health Alliance. Australian STI management guidelines for use in primary care; 2019; Available from: http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management. Accessed 927, 2020.
   Google Scholar
• Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections; 2017 Available from: http://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-1-2017-2-eng.pdf. Accessed 927, 2020.
   Google Scholar
• Unemo M. The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. Eur Surveill. 2012;17(47).
   Google Scholar
• The New Zealand Sexual Health Society. New Zealand guideline for the management of gonorrhoea, 2014, and response to the threat of antimicrobial resistance; 2014 Available from: https://www.nzshs.org/docman/guidelines/best-practice-guidelines/142-new-zealand-guideline-for-the-management-of-gonorrhoea-2014-and-response-to-the-threat-of-antimicrobial-resistance/file. Accessed 927, 2020.
   Google Scholar
• World Health Organization [homepage on Internet]. WHO guidelines for the treatment of Neisseria gonorrhoeae; 2016 Available from: http://apps.who.int/iris/bitstream/10665/246114/1/9789241549691-eng.pdf?ua=1. Accessed 613, 2020.
   Google Scholar
• Yin YP, Han Y, Dai XQ, et al. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016. PLoS Med. 2018;15(2):e1002499. doi:10.1371/journal.pmed.100249929408881
   PubMed Web of Science ®Google Scholar
• Yin YP. Guidelines for laboratory testing of sexually transmitted diseases. Beijing: People's Medical Publishing House (PMPH); 2019.
   Google Scholar
• Liu JW, Xu WQ, Zhu XY, et al. Gentamicin susceptibility of Neisseria gonorrhoeae isolates from 7 provinces in China. Infect Drug Resist. 2019;12:2471–2476. doi:10.2147/IDR.S21405931496761
   PubMed Web of Science ®Google Scholar
• World Health Organization [homepage on Internet]. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae; 2012 Available from: https://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/. Accessed 510, 2020.
   Google Scholar
• Xiao Y, Li L. China’s national plan to combat antimicrobial resistance. Lancet Infect Dis. 2016;16(11):1216–1218. doi:10.1016/S1473-3099(16)30388-727788972
   PubMed Web of Science ®Google Scholar
• Chen XS, Yin YP, Li XY. A ROADMAP plan to address research needs for gonococcal antimicrobial resistance in China. Clin Infect Dis. 2019;68(3):505–510. doi:10.1093/cid/ciy56629985996
   PubMed Web of Science ®Google Scholar
• Hiyama Y, Takahashi S, Sato T, et al. Evaluation of susceptibilities to carbapenems and faropenem against cephalosporin-resistant neisseria gonorrhoeae clinical isolates with penA mosaic alleles. Microbial Drug Resist (Larchmont, NY). 2019;25(3):427–433. doi:10.1089/mdr.2018.0263
   Web of Science ®Google Scholar
• Tesh LD, Shaeer KM, Cho JC, et al. Neisseria gonorrhoeae and fosfomycin: past, present and future. Int J Antimicrob Agents. 2015;46(3):290–296. doi:10.1016/j.ijantimicag.2015.05.00726145201
   PubMed Web of Science ®Google Scholar
• Yuan Z, He C, Yan S, Ke Y, Tang W. Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men. Clin Microbiol. 2016;22(6):507–512. doi:10.1016/j.cmi.2016.03.031
   Web of Science ®Google Scholar
• Yuan Y, Si S, Jiang J. Antibacterial activity of berberine. Acta Pharmaceutica Sinica. 2018;53:163–168.
   Google Scholar
• Wu LT, Tsou MF, Ho CC, Chuang JY, Kuo HM, Chung JG. Berberine inhibits arylamine N-acetyltransferase activity and gene expression in Salmonella typhi. Curr Microbiol. 2005;51(4):255–261. doi:10.1007/s00284-005-4569-716086103
   PubMed Web of Science ®Google Scholar
• Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry. 2008;47(10):3225–3234. doi:10.1021/bi701854618275156
   PubMed Web of Science ®Google Scholar
• Boberek JM, Stach J, Good L. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010;5(10):e13745.21060782
   PubMed Web of Science ®Google Scholar
• Sun D, Abraham SN, Beachey EH. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother. 1988;32(8):1274–1277. doi:10.1128/AAC.32.8.12742903716
   PubMed Web of Science ®Google Scholar
• Anonymous. Berberine. Alter Med Rev. 2000;5(2):175–177.
   Google Scholar
• Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22(8):999–1012.18618524
   PubMed Web of Science ®Google Scholar
• Unemo M, Golparian D, Sánchez-Busó L, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016;71(11):3096–3108. doi:10.1093/jac/dkw28827432602
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538–3545. doi:10.1128/AAC.00325-1121576437
   PubMed Web of Science ®Google Scholar
• Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273–1280. doi:10.1128/AAC.05760-1122155830
   PubMed Web of Science ®Google Scholar
• Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850–1851. doi:10.1056/NEJMc140810925372111
   PubMed Web of Science ®Google Scholar
• Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(2):381–383. doi:10.3201/eid2402.171756
   PubMed Web of Science ®Google Scholar
• Chen SC, Yin YP, Chen XS. Cephalosporin-resistant Neisseria gonorrhoeae clone, China. Emerg Infect Dis. 2018;24(4):804–806. doi:10.3201/eid2404.17181729553336
   PubMed Web of Science ®Google Scholar
• Eyre DW, Town K, Street T, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Eur Surveill. 2019;24(10).
   Google Scholar
• Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014;34(8):845–857. doi:10.1002/phar.143424782335
   PubMed Web of Science ®Google Scholar
• Hauser C, Hirzberger L, Unemo M, Furrer H, Endimiani A. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother. 2015;59(3):1605–1611. doi:10.1128/AAC.04536-1425547354
   PubMed Web of Science ®Google Scholar
• Yang F, Yan J, Zhang J, van der Veen S. Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China. Int J Antimicrob Agents. 2020;55(2):105846. doi:10.1016/j.ijantimicag.2019.11.00331760083
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Gallego A, Olay T, Mata JM. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy. 1977;23(Suppl 1):247–258. doi:10.1159/000222055832523
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. European committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters version 10.0; 2020; Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf. Accessed 510, 2020.
   Google Scholar
• Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs. 2010;19(10):1297–1307. doi:10.1517/13543784.2010.517745
   PubMed Web of Science ®Google Scholar
• Cybulska P, Thakur SD, Foster BC, et al. Extracts of Canadian first nations medicinal plants, used as natural products, inhibit neisseria gonorrhoeae isolates with different antibiotic resistance profiles. Sex Transm Dis. 2011;38(7):667–671. doi:10.1097/OLQ.0b013e31820cb16621301385
   PubMed Web of Science ®Google Scholar
• Li G, Chen Q, Chen J. In vitro bacteriostatic effects of 21 Chinese herbs on gonorrhea strains. J Clin Dermatol. 2003;334.
   Google Scholar
• Pan G-Y, Wang G-J, Liu X-D, Fawcett JP, Xie -Y-Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002;91(4):193–197. doi:10.1034/j.1600-0773.2002.t01-1-910403.x12530470
   PubMedGoogle Scholar
• Tan XS, Ma JY, Feng R, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013;8(10):e77969. doi:10.1371/journal.pone.007796924205048
   PubMed Web of Science ®Google Scholar
• Cernáková M, Kostálová D. Antimicrobial activity of berberine–a constituent of Mahonia aquifolium. Folia Microbiol (Praha). 2002;47(4):375–378. doi:10.1007/BF281869312422513
   PubMed Web of Science ®Google Scholar
• Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med. 2007;147(2):89–96. doi:10.7326/0003-4819-147-2-200707170-0000717638719
   PubMed Web of Science ®Google Scholar